David Stegner: How Fundamental Platelet Research Can Translate Into Therapeutic Innovation
David Stegner, Professor of Vascular Imaging at the Julius Maximilians University of Würzburg, reposted from Boehringer Ingelheim on LinkedIn:
”A strong example of how fundamental platelet research can translate into therapeutic innovation.
Work from University Hospital of Würzburg has identified GPVI as a key driver of thrombo-inflammation in acute ischemic stroke, directly linking platelet biology to clinical outcome.
The collaboration between Boehringer Ingelheim and Emfret Analytics now advances this concept toward clinical application.
Targeting GPVI offers a compelling strategy: inhibiting pathological platelet activation while preserving hemostasis – a critical requirement in stroke therapy.
For the field, this marks an important translational milestone.
For patients, it highlights the potential to improve outcomes beyond current standard-of-care.”
Quoting Boehringer Ingelheim‘s post:
”NEWS: We are collaborating with Emfret Analytics to advance a potential first‑in‑class antibody‑based approach for acute ischemic stroke.
For decades, we have helped transform stroke care.
By targeting the platelet receptor GPVI, this new approach aims to inhibit thrombus formation and growth while maintaining normal hemostasis – designed to complement standard‑of‑care therapies and further improve patient outcomes.”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida